Close Menu

J&J

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

The Wall Street Journal reports vaccine makers promise to not seek regulatory approval until there is evidence their SARS-CoV-2 vaccines are safe and effective.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

For a Vaccine

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.

The UK is partnering with pharmaceutical companies to sequence and analyze DNA samples from UK Biobank participants.

The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.

Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.

Pages

Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.

The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.

About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.

In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.